Most linked-to pages
From Glioblastoma Treatments
Jump to navigationJump to search
Showing below up to 50 results in range #1 to #50.
- Not specified (78 links)
- 3 (49 links)
- 4 (36 links)
- 2 (35 links)
- 1 (17 links)
- Not rated (9 links)
- Property:Has Toxicity Level (8 links)
- Property:Has Usefulness Rating (8 links)
- Property:Has treatment name (7 links)
- 2.5 (6 links)
- Not applicable (4 links)
- Property:Has Toxicity Explanation (4 links)
- 23 months median survival, with 47% at 2 years (3 links)
- 3.5 (3 links)
- 3 (awaiting research) (3 links)
- 3 - Under investigation (3 links)
- 5 (3 links)
- 6.1 months for all patients, 5.9 months for EGFR amplified patients (3 links)
- AVAglio trial: 16.8 months; RTOG trial: 15.7 months (3 links)
- BCNU (Carmustine) and Gliadel (Carmustine Wafers) (3 links)
- Bevacizumab (Avastin) (3 links)
- CBD (3 links)
- CBD (Cannabidiol) (3 links)
- CCNU (Lomustine) (3 links)
- Cannabigerol (CBG) (3 links)
- Cannabis (3 links)
- Cannabis and Cannabis-derived Products (e.g., Sativex) (3 links)
- Celebrex (Celecoxib) and Other NSAIDs (3 links)
- Chloroquine (3 links)
- Chloroquine and Hydroxychloroquine (3 links)
- Combination of Repurposed Drugs plus Temodar (3 links)
- Comparable to standard TMZ treatments, but timing affects management of side effects. (3 links)
- Disulfiram (Antabuse) (3 links)
- Ellagic Acid (3 links)
- Fish Oil (Omega-3 Fatty Acids: EPA and DHA) (3 links)
- Fish oil (3 links)
- Gamma-Linolenic Acid (GLA) (3 links)
- Garlic (Allium sativum) (3 links)
- Gliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months (3 links)
- ICT-107 has demonstrated potential in extending progression-free and overall survival in GBM patients, especially in specific subgroups. Its ability to target multiple tumor-associated antigens may offer a broader immunogenic response. (3 links)
- Isotretinoin (Accutane) (3 links)
- Keppra (3 links)
- Keppra (Levetiracetam) (3 links)
- MN-166 (Ibudilast) (3 links)
- Methadone (D,L-methadone) (3 links)
- Not applicable; studies focusing on PFS-6 as a primary endpoint (3 links)
- Not reached at a median follow-up of 5.8 months (3 links)
- Not specified in the provided text (3 links)
- PFS-6 value was 53% in a restricted patient population with overexpression of PDGFR (3 links)
- PSK (Polysaccharide Krestin) and other polysaccharides (3 links)